Stock 000078 SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shenzhen Neptunus Bioengineering Co., Ltd.

Equities

000078

CNE000000X95

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-03 EDT 		5-day change 1st Jan Change
2.21 CNY 0.00% Intraday chart for Shenzhen Neptunus Bioengineering Co., Ltd. -3.49% -29.62%
04-29 Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-29 Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan
MT
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shenzhen Neptunus Bioengineering to Set Up 150 Million Yuan Medical Equipment Unit
MT
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
FinVolution's Shares Fall Wednesday as Citigroup Downgrade Follows Lower Q4 Non-GAAP Earnings, Net Revenue
MT
FinVolution Group's Q4 Non-GAAP Earnings Decline, Revenue Rises; CEO Steps Down; Annual Dividend Raised
MT
Shenzhen Neptunus Bioengineering Warns of Loss in 2022
MT
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hongta Securities Chairman, Two Others Resign as H1 Profit Halves
MT
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Shenzhen Neptunus Bioengineering Co., Ltd. agreed to acquire Shanghai Julikang Medical Technology Group Co., Ltd. from Zhuhai Haiwang Huaxia Equity Investment Fund (L.P.), managed by Shenzhen Huaxia Dexin Fund Management Co., Ltd. for CNY 63 million.
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 000078 Stock
  4. News Shenzhen Neptunus Bioengineering Co., Ltd.
  5. Highlights